This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Xopenex Inhalation Solution
Drug Names(s): levalbuterol HCL, Xopenex for Nebulizer
Description: As of its October 2009 acquisition of Sepracor (renamed Sunovion), Dainippon now reports revenue for Xopenex HFA and the inhalation product under Xopenex.
The active ingredient of Xopenex, levalbuterol, is a single isomer formulation of the widely prescribed racemic albuterol. It binds to human beta adrenergic receptors on smooth muscle cells of airways. Activation of the beta adrenergic receptors results in the relaxation of the airways. As well as being a solution to use with a nebulizer, Xopenex is available as a metered dose inhaler using an HFA propellant (Xopenex HFA MDI).
Deal Structure: Xopenex Inhalation Solution was originally developed by Sepracor.
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share. The acquisition was completed in October 2009.
Akorn and Sumitomo
In September 2014, Akorn announced that it has signed a definitive agreement to acquire certain rights to short-acting bronchodilator Xopenex (levalbuterol HCI) Inhalation Solution (IS) from Sunovion, a Sumitomo subsidiary, for $45 million, paid in cash at closing, net of certain liabilities.
Partners: Sumitomo Dainippon Pharma Co., Ltd.
Xopenex Inhalation Solution News
Pink Sheet Sepracor Xopenex
Pink Sheet Xopenex pediatric use
Additional information available to subscribers only: